Literature DB >> 21811101

Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Soma Ghosh1, Jordan M Winter, Kalpesh Patel, Scott E Kern.   

Abstract

The DNA replicative gene, thymidylate synthase (TYMS), is inhibited upon treatment with the anticancer drug 5-fluorouracil (5FU). TYMS has 28-bp tandem repeat sequences or VNTR (variable numbers of tandem repeats) in the 5'-untranslated region (5'-UTR). The number of these repeats is variable in any given population, but the most prevalent are double (2R) and triple (3R) repeat sequences. A single G/C nucleotide polymorphism in the triple repeat sequence gives rise to a 3Rc or a 3Rg triple repeat structure. A widely cited literature used plasmid constructs of the 5'-UTR and proposed that genotyping the TYMS UTRs would predict the efficiency of Tyms protein translation, justifying altered therapeutic dosage of 5FU. Prior studies had unusual features in experimental design, such as using the firefly Kozak sequence in place of the native human TYMS Kozak sequence to determine the ribosomal translational efficiency of TYMS mRNA. Our results using transient transfection, antibiotic-selected pools of transfected cells, and stably transfected clones, while using plasmids having native human Kozak sequence, refute the earlier results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811101      PMCID: PMC3218528          DOI: 10.4161/cbt.12.8.16867

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

1.  Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles.

Authors:  Huai-Rong Luo; Xue-Mei Lü; Yong-Gang Yao; Nobuyuki Horie; Keiichi Takeishi; Lynn B Jorde; Ya-Ping Zhang
Journal:  Biochem Genet       Date:  2002-02       Impact factor: 1.890

2.  Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.

Authors:  C E de Bock; M B Garg; N Scott; J A Sakoff; F E Scorgie; S P Ackland; L F Lincz
Journal:  Pharmacogenomics J       Date:  2010-06-08       Impact factor: 3.550

3.  Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression.

Authors:  K Kawakami; D Salonga; J M Park; K D Danenberg; H Uetake; J Brabender; K Omura; G Watanabe; P V Danenberg
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

5.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.

Authors:  S T Pullarkat; J Stoehlmacher; V Ghaderi; Y P Xiong; S A Ingles; A Sherrod; R Warren; D Tsao-Wei; S Groshen; H J Lenz
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

6.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.

Authors:  E Villafranca; Y Okruzhnov; M A Dominguez; J García-Foncillas; I Azinovic; E Martínez; J J Illarramendi; F Arias; R Martínez Monge; E Salgado; S Angeletti; A Brugarolas
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

Review 7.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.

Authors:  Ryuta Fujii; Akiyoshi Seshimo; Shingo Kameoka
Journal:  Int J Clin Oncol       Date:  2003-04       Impact factor: 3.402

9.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity.

Authors:  Michael V Mandola; Jan Stoehlmacher; Susan Muller-Weeks; Gregory Cesarone; Mimi C Yu; Heinz-Josef Lenz; Robert D Ladner
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

10.  Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity.

Authors:  Kazuyuki Kawakami; Yoshinori Ishida; Kathleen D Danenberg; Kenji Omura; Go Watanabe; Peter V Danenberg
Journal:  Jpn J Cancer Res       Date:  2002-11
View more
  7 in total

Review 1.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

2.  Thymidylate synthase polymorphisms and risk of conotruncal heart defects.

Authors:  Huiping Zhu; Wei Yang; Nathan Shaw; Spencer Perloff; Suzan L Carmichael; Richard H Finnell; Gary M Shaw; Edward J Lammer
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

3.  A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

Authors:  Dan Rosmarin; Claire Palles; Alistair Pagnamenta; Kulvinder Kaur; Guillermo Pita; Miguel Martin; Enric Domingo; Angela Jones; Kimberley Howarth; Luke Freeman-Mills; Elaine Johnstone; Haitao Wang; Sharon Love; Claire Scudder; Patrick Julier; Ceres Fernández-Rozadilla; Clara Ruiz-Ponte; Angel Carracedo; Sergi Castellvi-Bel; Antoni Castells; Anna Gonzalez-Neira; Jenny Taylor; Rachel Kerr; David Kerr; Ian Tomlinson
Journal:  Gut       Date:  2014-03-19       Impact factor: 23.059

4.  Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.

Authors:  Soma Ghosh; M Zulfiquer Hossain; Michael Borges; Michael G Goggins; Roxann G Ingersoll; James R Eshleman; Alison P Klein; Scott E Kern
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

5.  Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.

Authors:  Emilia Balboa-Beltrán; Raquel Cruz; Angel Carracedo; Francisco Barros
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

6.  Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer.

Authors:  José da Silva Nogueira; Fernando Augusto de Lima Marson; Carmen Sílvia Bertuzzo
Journal:  BMC Res Notes       Date:  2012-12-06

7.  TYMS gene 5'- and 3'-untranslated region polymorphisms and risk of non-syndromic cleft lip and palate in an Indian population.

Authors:  Jyotsna Murthy; G Venkatesh Babu; L V K S Bhaskar
Journal:  J Biomed Res       Date:  2015-04-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.